229 related articles for article (PubMed ID: 12374238)
21. Successful use of infliximab for treating fistulizing pouchitis with severe extraintestinal manifestation: a case report.
Molnar T; Farkas K; Nagy F; Wittmann T
Inflamm Bowel Dis; 2008 Dec; 14(12):1752-3. PubMed ID: 18452207
[No Abstract] [Full Text] [Related]
22. Improvement of idiopathic pyoderma gangrenosum during treatment with anti-tumor necrosis factor alfa monoclonal antibody.
Dini V; Romanelli M; Bertone M; Talarico S; Bombardieri S; Barachini P
Int J Low Extrem Wounds; 2007 Jun; 6(2):108-13. PubMed ID: 17558009
[TBL] [Abstract][Full Text] [Related]
23. Failure of sublesional infliximab injection for refractory parastomal pyoderma gangrenosum in a patient with Crohn's disease.
Teich N
Tech Coloproctol; 2014 Oct; 18(10):965-6. PubMed ID: 24965074
[No Abstract] [Full Text] [Related]
24. Pyoderma gangrenosum associated with ulcerative colitis: response to infliximab.
López San Román A; Bermejo F; Aldanondo I; Carrera E; Boixeda D; Muñoz Zato E
Rev Esp Enferm Dig; 2004 Jun; 96(6):420-2; 422-4. PubMed ID: 15230672
[TBL] [Abstract][Full Text] [Related]
25. Corticosteroid-resistant pyoderma gangrenosum associated with Crohn's disease: rapid cure with infliximab.
Grange F; Djilali-Bouzina F; Weiss AM; Polette A; Guillaume JC
Dermatology; 2002; 205(3):278-80. PubMed ID: 12399677
[TBL] [Abstract][Full Text] [Related]
26. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome.
Stichweh DS; Punaro M; Pascual V
Pediatr Dermatol; 2005; 22(3):262-5. PubMed ID: 15916580
[TBL] [Abstract][Full Text] [Related]
27. [Infliximab for a girl with refractory pyoderma gangrenosum].
Nozawa T; Hara R; Kinoshita J; Sano F; Miyamae T; Imagawa T; Mori M; Hirokado M; Takahashi K; Inayama Y; Yokota S
Nihon Rinsho Meneki Gakkai Kaishi; 2008 Dec; 31(6):454-9. PubMed ID: 19122376
[TBL] [Abstract][Full Text] [Related]
28. Certolizumab pegol - A new therapeutic option for refractory disseminated pyoderma gangrenosum associated with Crohn's disease.
Hurabielle C; Schneider P; Baudry C; Bagot M; Allez M; Viguier M
J Dermatolog Treat; 2016; 27(1):67-9. PubMed ID: 25909366
[TBL] [Abstract][Full Text] [Related]
29. Use of infliximab in a patient with pyoderma gangrenosum and rheumatoid arthritis.
Tada M; Nakanishi T; Hirata C; Okano T; Sugioka Y; Wakitani S; Nakamura H; Koike T
Mod Rheumatol; 2010 Dec; 20(6):598-601. PubMed ID: 20680379
[TBL] [Abstract][Full Text] [Related]
30. Pyoderma gangrenosum outside the context of inflammatory bowel disease treated successfully with infliximab.
Swale VJ; Saha M; Kapur N; Hoffbrand AV; Rustin MH
Clin Exp Dermatol; 2005 Mar; 30(2):134-6. PubMed ID: 15725238
[TBL] [Abstract][Full Text] [Related]
31. Is there a role for infliximab in the current therapy of hidradenitis suppurativa? A report of three treated cases.
Moschella SL
Int J Dermatol; 2007 Dec; 46(12):1287-91. PubMed ID: 18173525
[TBL] [Abstract][Full Text] [Related]
32. Parastomal pyoderma gangrenosum in inflammatory bowel disease.
Tjandra JJ; Hughes LE
Dis Colon Rectum; 1994 Sep; 37(9):938-42. PubMed ID: 8076495
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic hotline. Infliximab for treatment of resistant pyoderma gangrenosum associated with ulcerative colitis and psoriasis. A case report.
Baglieri F; Scuderi G
Dermatol Ther; 2010; 23(5):541-3. PubMed ID: 20868408
[TBL] [Abstract][Full Text] [Related]
34. Tumor necrosis factor-α inhibitors for the treatment of pyoderma gangrenosum not associated with inflammatory bowel diseases: A multicenter retrospective study.
Rousset L; de Masson A; Begon E; Villani A; Battistella M; Rybojad M; Jachiet M; Bagot M; Bouaziz JD; Lepelletier C
J Am Acad Dermatol; 2019 Apr; 80(4):1141-1143. PubMed ID: 30342166
[No Abstract] [Full Text] [Related]
35. Topical tacrolimus (FK506) in the treatment of recalcitrant parastomal pyoderma gangrenosum associated with Crohn's disease: report of two cases.
Khurrum Baig M; Marquez H; Nogueras JJ; Weiss EG; Wexner SD
Colorectal Dis; 2004 Jul; 6(4):250-3. PubMed ID: 15206967
[TBL] [Abstract][Full Text] [Related]
36. The role of anti-tumor necrosis factor-alpha therapy in Pyoderma gangrenosum associated with inflammatory bowel disease.
Reguiaï Z; Grange F
Am J Clin Dermatol; 2007; 8(2):67-77. PubMed ID: 17428111
[TBL] [Abstract][Full Text] [Related]
37. Intravenous cyclosporine therapy in the treatment of pyoderma gangrenosum secondary to Crohn's disease.
Carp JM; Onuma E; Das K; Gottlieb AB
Cutis; 1997 Sep; 60(3):135-8. PubMed ID: 9314617
[TBL] [Abstract][Full Text] [Related]
38. [Pyoderma gangrenosum, a nonintestinal manifestation of Lesniowski-Crohn's disease in a 15 years old girl].
Müller L; Bala G; Kuczyńska R; Czerwionka-Szaflarska M
Med Wieku Rozwoj; 2006; 10(2):463-73. PubMed ID: 16825717
[TBL] [Abstract][Full Text] [Related]
39. Adalimumab treatment for peristomal pyoderma gangrenosum associated with Crohn's disease.
Alkhouri N; Hupertz V; Mahajan L
Inflamm Bowel Dis; 2009 Jun; 15(6):803-6. PubMed ID: 18942748
[No Abstract] [Full Text] [Related]
40. Treatment of idiopathic pyoderma gangrenosum with infliximab: induction dosing regimen or on-demand therapy?
Adişen E; Oztaş M; Gürer MA
Dermatology; 2008; 216(2):163-5. PubMed ID: 18216480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
